{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-034786","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.699713+00:00","generated_at":"2026-05-15T08:53:53.198610+00:00","sec_items":["5.02","5.03","8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action","bullets":["On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.","Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.","Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.","Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.","Purported new board approved business expansions without authorization; company disputes them."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-034786","json":"https://secwatch.observer/filing/0001213900-26-034786.json","markdown":"https://secwatch.observer/filing/0001213900-26-034786.md","text":"https://secwatch.observer/filing/0001213900-26-034786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/0001213900-26-034786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/ea0283550-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:53:53.198610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75cc78fd89876ec222c9611adb20eb9781c4a6d5","claim":"Apimeds Pharmaceuticals US, Inc.: Attempted amendment to the Amended and Restated Bylaws via stockholder written consent, which the company asserts is invalid.","evidence_excerpt":"Because the Stockholder Consent is invalid, the amendment to the Amended and Restated Bylaws of the Company made in connection with the Stockholder Consent is invalid.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026034786/0001213900-26-034786-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}